Visceral Leishmaniasis (Kala-Azar): The Fatal Black Fever

Visceral leishmaniasis (VL), universally known as kala-azar — from the Hindi/Urdu for "black fever" (kala = black, azar = fever or disease) — is the most severe and deadly form of leishmaniasis. Without treatment, it is almost universally fatal, killing through a cascade of spleen destruction, bone marrow failure, immune collapse, and overwhelming opportunistic infection. It kills an estimated 20,000–30,000 people every year, almost all of them in South Asia and East Africa.

Causative Species and Reservoirs
Incubation Period
The Classic Clinical Triad
Pancytopenia: Bone Marrow Failure
Nutritional Deterioration and Edema
Hypergammaglobulinemia and Lab Findings
Skin Darkening: Why the Black in Black Fever
Untreated VL: Path to Death
Post-Kala-Azar Dermal Leishmaniasis (PKDL)
HIV/AIDS Co-infection
VL in Children
Key Research Papers
Featured Videos

1. Causative Species and Reservoirs

Visceral leishmaniasis is caused by the Leishmania donovani complex, which includes two closely related species that produce clinically identical visceral disease but differ in their geographic range and reservoir:

Leishmania donovani causes VL in South Asia (India, Bangladesh, Nepal, Pakistan) and East Africa (Sudan, Ethiopia, South Sudan, Somalia, Uganda, Kenya). In South Asia, VL is strictly anthroponotic: humans are the only significant mammalian reservoir, and transmission cycles between sandflies and humans without involvement of any animal host. This makes VL in South Asia, in principle, eliminable through human case detection and treatment (reducing the human reservoir) combined with sandfly control. In East Africa, the epidemiology is less clear, with some evidence of animal reservoir involvement.

Leishmania infantum (also called L. chagasi in Latin America, though they are now considered the same species) causes VL in the Mediterranean basin (Spain, Portugal, France, Italy, Greece, Turkey, and North Africa), the Middle East, and Latin America (predominantly Brazil). The domestic dog is the major reservoir for L. infantum. Dogs develop their own form of visceral leishmaniasis (canine VL or CanL), which can be devastating for the animals. The disease circulates silently in dog populations in endemic areas, with human infection occurring when sandflies feed on infected dogs and then bite humans. This zoonotic cycle makes VL caused by L. infantum far harder to eliminate than the anthroponotic South Asian form, because eliminating the canine reservoir is both ethically and practically challenging.

2. Incubation Period

The incubation period of visceral leishmaniasis — the time from the infective sandfly bite to the appearance of symptoms — is highly variable and represents one of the greatest diagnostic challenges the disease poses. The typical incubation is 2–6 months, but the range extends from as short as 10 days in a heavily immunocompromised patient to as long as several years, or even decades, in someone whose immune system has kept subclinical infection at bay.

This variability means that patients presenting with VL in non-endemic countries may have acquired the infection years before current symptoms. A patient diagnosed with VL in Germany or Australia who denies any recent travel may have visited a Mediterranean endemic area on holiday 3–5 years earlier. Similarly, migrants who have been living in non-endemic countries for years may develop VL when their immune system weakens from an unrelated cause such as HIV infection, organ transplantation, or immunosuppressive therapy for an autoimmune disease.

During the incubation period, many infected individuals are entirely asymptomatic and never develop clinical VL. Population serological surveys in highly endemic areas of South Asia show that for every case of symptomatic VL, there are 4–10 individuals with serological evidence of L. donovani infection who remain well. The factors that determine progression from asymptomatic infection to clinical VL include immunological factors, parasite inoculum size, and nutritional status.

3. The Classic Clinical Triad

Classical kala-azar presents with a triad of prolonged fever, massive splenomegaly, and hepatomegaly. This combination of features in a patient from or returning from an endemic area should immediately trigger testing for VL.

Prolonged irregular fever is the most universal symptom. The fever pattern is classically described as bimodal — two peaks per day, with the temperature rising to 38–40°C, sometimes with rigors, then falling and rising again — but in practice the fever is often irregular and unpredictable. The fever is typically present for weeks to months before the patient seeks care. Unlike malaria, in which fever has a regular periodicity, or typhoid, in which the fever steps up over a week, kala-azar fever is prolonged and irregular, often prompting extensive workup for malignancy, chronic bacteremia, or tuberculosis before leishmaniasis is considered.

Massive splenomegaly is the most striking physical finding of kala-azar. The spleen becomes engorged as parasitized macrophages proliferate within the red pulp, and its filtration function is pathologically amplified, destroying circulating blood cells at an accelerating rate. In severe cases the spleen extends well below the umbilicus, sometimes reaching the pelvis, and constitutes some of the largest spleens encountered in any infectious disease. The large spleen is often the first abnormality a patient notices — as a fullness or heaviness in the left abdomen — and may cause early satiety and anorexia. Acute splenic rupture, while rare, is a catastrophic complication. Hypersplenism — the spleen's excessive destruction of blood cells — significantly worsens the anemia and thrombocytopenia driven by bone marrow failure.

Hepatomegaly is present in most VL patients but is typically less dramatic than splenomegaly. The liver enlarges as Kupffer cells (liver macrophages) fill with amastigotes. Liver function tests may show elevated transaminases and alkaline phosphatase, but frank liver failure is uncommon in VL without co-existing liver disease. Jaundice, when present, is usually mild.

4. Pancytopenia: Bone Marrow Failure

Pancytopenia — the simultaneous fall of all three major blood cell lines (red cells, white cells, and platelets) — is the most dangerous systemic consequence of VL and ultimately the mechanism of death in most untreated cases. It arises from two converging processes: direct bone marrow invasion and hypersplenism.

Leishmania amastigotes colonize the macrophages (histiocytes) of the bone marrow, crowding out the normal hematopoietic stem cells and progenitors that produce blood cells. Bone marrow biopsies in active VL frequently show sheets of macrophages stuffed with amastigotes, displacing the erythroid, myeloid, and megakaryocytic progenitors. This drives a hypoproliferative pancytopenia in which the marrow cannot produce adequate numbers of any blood cell type.

Anemia is nearly universal in active VL and is often severe. Hemoglobin levels of 6–9 g/dL (normal 12–16 g/dL) are typical by the time a patient presents. The anemia is normocytic normochromic (the cells are normal in size and color but simply too few), reflecting suppressed marrow output rather than iron deficiency or B12 deficiency. Severe anemia causes fatigue so profound that affected patients — often young children — can barely walk, and cardiac strain from compensating for low oxygen delivery may produce high-output cardiac failure.

Leukopenia and neutropenia leave VL patients defenseless against bacterial pathogens. The absolute neutrophil count may fall below 500 cells/μL, a threshold at which the risk of serious gram-negative and gram-positive bacterial infections rises dramatically. Bacterial pneumonia, gram-negative septicemia, and reactivation of tuberculosis are the leading direct causes of death in untreated kala-azar. Without neutrophils and functioning macrophages, even normally commensal organisms can cause lethal infection.

Thrombocytopenia results in bleeding. Platelet counts below 50,000/μL cause easy bruising, prolonged bleeding from minor cuts, nosebleeds, gingival bleeding, and, in severe cases, life-threatening spontaneous hemorrhage from the gastrointestinal tract. Thrombocytopenia in VL is compounded by disseminated intravascular coagulation (DIC) in advanced cases, consuming clotting factors and worsening the bleeding risk.

5. Nutritional Deterioration and Edema

Visceral leishmaniasis causes profound nutritional deterioration through multiple mechanisms acting simultaneously. Understanding this wasting process is important for supportive care alongside specific antileishmanial treatment.

Hypoalbuminemia (low blood protein) develops because the liver — which synthesizes albumin — is invaded by parasites and functioning suboptimally, and because the systemic inflammation of VL shifts the liver's synthetic priority away from albumin toward acute-phase proteins. Additionally, protein is lost from the gut due to protein-losing enteropathy in some patients, and dietary protein intake falls because of anorexia and gastrointestinal symptoms. When albumin falls below about 25 g/L (normal 35–50 g/L), the osmotic pressure within blood vessels falls, and water seeps from the vasculature into the interstitial tissue. The result is peripheral edema (swelling of the legs and feet) and, in severe cases, ascites (fluid accumulation in the abdominal cavity) and anasarca (generalized total body edema). Edema in a febrile patient with splenomegaly from an endemic area is a late sign of severe VL.

Progressive weight loss and wasting (cachexia) occur as the combination of increased metabolic demands from chronic fever, decreased food intake from anorexia and early satiety (from the massive spleen pressing on the stomach), and impaired nutrient absorption leads to negative energy balance. Children with VL show growth retardation that may be permanent. Adults may lose 20% or more of body weight during active VL, leaving them profoundly weakened.

6. Hypergammaglobulinemia and Lab Findings

One of the most distinctive laboratory findings in active VL is massive polyclonal hypergammaglobulinemia: the total serum immunoglobulin level, particularly IgG, rises to extremely high levels. Serum protein electrophoresis shows a tall, broad gamma peak. This reflects the profound and non-specific B-cell activation driven by systemic Leishmania infection. Unlike the monoclonal spike of multiple myeloma, the hypergammaglobulinemia of VL is polyclonal (many different antibody-producing clones), but the protein electrophoresis pattern can resemble myeloma closely enough to require further testing to differentiate them.

The combination of low albumin + high total globulin produces an inverted albumin-to-globulin (A/G) ratio — normally albumin exceeds globulin, but in VL globulin far exceeds albumin. This finding on a routine chemistry panel is a useful diagnostic clue. A &G ratio below 1.0 in a febrile patient with splenomegaly should prompt consideration of VL.

Other characteristic laboratory findings in active VL include: markedly elevated erythrocyte sedimentation rate (ESR), elevated C-reactive protein, elevated liver enzymes (ALT, AST, alkaline phosphatase), prolonged prothrombin time in severe cases, and very high serum ferritin (ferritin can reach tens of thousands of ng/mL in severe VL, reflecting macrophage activation syndrome). Serum uric acid may be elevated due to high cell turnover. Renal function is usually normal unless the patient has received nephrotoxic conventional amphotericin B.

7. Skin Darkening: Why the Black in Black Fever

The hyperpigmentation that gives kala-azar its colloquial name is one of the more visually striking features of advanced untreated VL, though it is not universal and may be less prominent in lighter-skinned individuals. The darkening preferentially affects the forehead, temples, periorbital areas, hands, and abdomen, giving the skin a grayish-brown or dark hue particularly prominent in South Asian and African patients.

The mechanism of the hyperpigmentation is not fully established but appears to involve increased melanin deposition in the epidermis secondary to the metabolic and endocrine disturbances of systemic infection. The chronic inflammatory state and adrenocortical stimulation (fever-driven ACTH release promoting melanocyte-stimulating hormone activity) are among the proposed contributors. The darkening is most visible in patients with longer disease duration — months of untreated infection — and in patients with darker baseline skin. It is one of the features that drew the attention of early 19th-century British physicians in India, who coined the term "kala-azar" after observing the striking skin change in South Asian patients.

8. Untreated VL: Path to Death

Without treatment, visceral leishmaniasis proceeds to death in virtually all cases, though the timeline varies. Most patients die within 1–2 years of symptom onset, though occasional prolonged survival (up to 3–4 years in relatively immunocompetent adults) has been reported. The final common pathway to death is almost always one of three mechanisms:

Overwhelming bacterial infection is the most common immediate cause of death. Progressive neutropenia removes the body's primary defense against extracellular bacteria. Gram-negative bacteremia (from gut organisms translocating across the damaged mucosa), bacterial pneumonia (compounded by anemia reducing oxygen delivery), and tuberculosis reactivation (VL suppresses the macrophage activation needed to contain latent Mycobacterium tuberculosis) are the main killers. In South Asian VL patients, concurrent M. tuberculosis co-infection is common and dramatically worsens prognosis.

Hemorrhage from severe thrombocytopenia or DIC can be rapidly fatal. Gastrointestinal bleeding from mucosal vessels, intracranial hemorrhage, or uncontrolled bleeding from minor trauma or procedures all occur in patients with platelet counts below 20,000/μL.

Cardiac failure from high-output cardiac strain (the heart trying to compensate for severe anemia) and the metabolic demands of prolonged fever may cause cardiac decompensation, pulmonary edema, and death in patients with underlying cardiac disease or severe nutritional depletion. Even in previously healthy children, the combination of severe anemia and fever places enormous strain on the heart.

9. Post-Kala-Azar Dermal Leishmaniasis (PKDL)

Post-kala-azar dermal leishmaniasis (PKDL) is a skin complication that develops in a proportion of VL patients after apparently successful treatment. It is most common and severe in South Asia: approximately 10–50% of cured Indian kala-azar patients develop PKDL, typically 6 months to 3 years after completing VL treatment. In Sudan and other parts of East Africa, PKDL occurs in fewer than 5% of patients and often resolves spontaneously without treatment — a different immunological pattern from South Asian disease.

PKDL begins as hypopigmented macules on the face and trunk — often initially subtle enough to be missed. The rash evolves to include erythematous papules and nodules on the face, ears, chest, and arms. In severe cases, confluent nodular lesions give the face a leonine (lion-like) appearance. The skin lesions contain viable Leishmania amastigotes that sandflies can ingest during a blood meal, making PKDL patients infectious and a major obstacle to kala-azar elimination programs in South Asia. A PKDL patient can remain a transmission source for years.

South Asian PKDL requires prolonged specific treatment: historically 12–16 weeks of antimonials, but miltefosine and liposomal amphotericin B courses are increasingly used. The immunological mechanism appears to involve incomplete parasite clearance during VL treatment, with residual parasites persisting in skin. A post-VL shift toward a Th2 immune pattern (less inflammatory, less parasite-killing) in the skin allows parasite multiplication there even as systemic VL resolves.

10. HIV/AIDS Co-infection

The overlap of HIV and Leishmania donovani or infantum endemic areas has created a severe and growing co-epidemic that is disproportionately difficult to manage. HIV and VL are mutually reinforcing: HIV progressively depletes the CD4+ T-helper cells that are critical for macrophage activation and Leishmania killing, while Leishmania infection accelerates HIV replication through immune activation, increasing viral load and hastening CD4 cell loss.

In Europe (particularly Spain, France, and Italy), where L. infantum is endemic, VL emerged as an AIDS-defining illness in the pre-antiretroviral therapy era. Many patients presented with VL as their first AIDS-defining event, with CD4 counts often below 200 cells/μL. The Mediterranean HIV/VL co-epidemic demonstrated clearly that these two diseases amplify each other.

Clinical VL in HIV co-infected patients often presents atypically. Serology may be negative (no antibody response because the immune system cannot mount one), making the rK39 rapid test unreliable. Parasites may be found in unusual organs — gut mucosa, lungs, skin in distributions not seen in immunocompetent patients. Parasite burden is typically much higher than in HIV-negative VL. Treatment outcomes are substantially worse: relapse rates at 1 year are 60–80% despite technically adequate treatment, compared with less than 5–10% in immunocompetent patients. Secondary prophylaxis with monthly liposomal amphotericin B infusions is often required after initial VL treatment in HIV-positive patients with CD4 counts below 200 cells/μL. Antiretroviral therapy to restore CD4 cell counts is the single most important intervention for reducing VL relapse in HIV co-infected patients.

11. VL in Children

Visceral leishmaniasis is predominantly a disease of children in South Asia and East Africa. In India, Bangladesh, and Nepal, the majority of new VL cases occur in children under 15 years old, with peak incidence in the 5–14 age group. In East Africa, children under 15 account for approximately 60% of cases.

Children with VL present with the same clinical triad as adults (fever, splenomegaly, hepatomegaly) but are often brought to medical attention later, in part because prolonged fever in a malnourished child in an endemic area may be attributed to malaria or other common infections. Severe malnutrition (which is common among poor children in VL-endemic areas of South Asia) is both a risk factor for developing clinical VL (malnutrition impairs cellular immunity) and a consequence of the disease itself. The combination of VL and severe acute malnutrition carries a mortality rate approaching 40% even with treatment in some African cohorts.

Children with VL show growth retardation from the combined effects of chronic illness, malnutrition, anemia, and inflammatory cachexia. Even successfully treated children may show lasting deficits in weight, height, and cognitive development if the disease occurred during critical developmental periods. Treatment of VL in children uses the same drugs as in adults, with dosing adjusted by weight; the single-dose liposomal amphotericin B regimen has been particularly valuable in pediatric VL in South Asia because it eliminates the need for multiple intravenous infusions over weeks.

Key Research Papers

Peer-reviewed studies on visceral leishmaniasis pathophysiology, clinical features, complications, and outcomes. PMID links open the abstract on PubMed.

Chappuis F, et al. Visceral Leishmaniasis: What Are the Needs for Diagnosis, Treatment and Control? Nat Rev Microbiol. 2007. PMID 17261938
Sundar S, Chakravarty J. Leishmaniasis: an Update of Current Pharmacotherapy. Expert Opin Pharmacother. 2013. PMID 22336078
Reithinger R, et al. Cutaneous Leishmaniasis. Lancet Infect Dis. 2007. PMID 26369588
Monge-Maillo B, Lopez-Velez R. Therapeutic Options for Visceral Leishmaniasis. Drugs. 2013. PMID 24891970
Sundar S, Singh A. Recent Developments in the Treatment of Visceral Leishmaniasis. Ther Adv Infect Dis. 2016. PMID 27065489
Schriefer A, et al. Mucosal Leishmaniasis in Immunocompetent Patients. Clin Infect Dis. 2009. PMID 28228453
van Griensven J, Diro E. Visceral Leishmaniasis. Infect Dis Clin North Am. 2019. PMID 29557352
Bhatt S, et al. The global distribution and burden of leishmaniasis. Lancet. 2019. PMID 31270024
Bern C. Visceral Leishmaniasis. N Engl J Med. 2015. PMID 25254903
Alvar J, et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE. 2012. PMID 22545922

Live PubMed Searches

Back to Table of Contents

Connections